Navigation Links
Inflection Biosciences licenses preclinical oncology programs from the CNIO
Date:6/4/2013

Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced that it has entered into a license agreement with the Spanish National Cancer Research Centre (CNIO) for the exclusive, worldwide rights to develop and commercialise several novel kinase inhibitors for the treatment of cancer.

The compounds leverage the CNIO's considerable expertise in drug discovery and comprise a novel pan-PIM kinase inhibitor program and a number of unique multi-targeting kinase inhibitors combining activity on PIM kinase and additional kinases including the phosphoinositide-3 kinase and the mammalian target of rapamycin (PI3K/mTOR) pathway. All molecules have shown good activity in preclinical models, are orally- available with excellent pharmaceutical properties.

Dr María Blasco, Director of CNIO added "It is a great satisfaction for the CNIO to join forces with the experienced team at Inflection Biosciences, allowing us to take full advantage of our ability to innovate cancer treatments."

Dr Michael O'Neill, Co-Founder and Director of Research and Development at Inflection Biosciences commented "Following an extensive global search we are delighted to have secured assets in late preclinical stages of development of this quality and potential and from an organisation recognised internationally for the quality of its cancer research and its drug discovery programs."


'/>"/>

Contact: Press Office
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)
Source:Eurekalert

Page: 1

Related biology news :

1. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
2. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
3. 3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology
4. Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement For Plasmid DNA Production
5. Ben-Gurion U. licenses drug delivery platform for central nervous system diseases to NY biotech firm
6. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
7. Preclinical studies use specialized ultrasound to detect presence of cancer
8. Preclinical study shows potential of new technologies to detect response to cancer therapy earlier
9. AACR news: Paragazole excels in preclinical models of triple-negative breast cancer
10. ESMO 2012 Congress: A path for medical oncology innovations
11. TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2018)... PHILADELPHIA, Pa. (PRWEB) , ... November 27, 2018 ... ... consulting firm , welcomes David Pepe, P.E., as Chief Operating Officer (COO). ... to lead operations and direct the company’s internal functions. Dave will also ...
(Date:11/27/2018)... (PRWEB) , ... November 26, 2018 , ... PulseEd™ uses ... of low-intensity, high-frequency sound waves to stimulate blood flow to the penis. Regular and ... clogged with age, is necessary for good erectile function. The recorded results of SWT ...
(Date:11/27/2018)... ... November 27, 2018 , ... LabArchives today announced a ... integrate the LabArchives Classroom Edition with Current Protocols Essential Laboratory Techniques for use ... January of 2019. , The integration of LabArchives Classroom Edition and ...
Breaking Biology News(10 mins):
(Date:11/20/2018)... Ga. (PRWEB) , ... November 19, 2018 , ... Patients ... receive custom dental implants from Dr. Dan Myers at THE DENTIST Centers ... dental implant placement and restorations for the last 20 years. He now offers skilled ...
(Date:11/13/2018)... ... 12, 2018 , ... AseptiScope(TM), Inc. announces it is advancing ... published last week, confirm pose a significant health risk. The two large ... stethoscopes are often improperly or rarely disinfected. In the AJIC November 6 issue, ...
(Date:11/11/2018)... ... ... Triple W, an innovator of connected health devices, today announced that it has ... the first health tech wearable device for incontinence that monitors how full your bladder ... was made during CES Unveiled New York, an invite-only tech event bringing together top ...
(Date:11/7/2018)... BEDFORD, Mass. (PRWEB) , ... November 07, 2018 , ... ... control system for algae at AzCATI, the Arizona Center for Algae Technology and Innovation ... to facilitate process development and trials for those involved with algal and predator control ...
Breaking Biology Technology: